Although VEGF has essential functions in the pathophysiology of the cardiovascular system, several adverse events have been reported after the administration of anti-VEGF agents, including thromboembolic events, myocardial infarction, stroke, hypertension, gastrointestinal perforations, and kidney disease7–9. The gene discussed is VEGFA; the disease is Stroke.